Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 9/20 | 0.55 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.55 |
| ▸ | PLK1 | P53350 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30497489 | 1.00 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL517751 | 0.86 | ALDH1A1 (0.62) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL517750 | 0.86 | ALDH1A1 (0.62) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL12337622 | 0.83 | LGMN (0.41) | — | |
| SCHEMBL30936846 | 0.83 | MAPT (0.40) | ALDH1A1LMNAMAPTMAPK1TDP1 | |
| SCHEMBL25261530 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL29364229 | 0.83 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL310477 | 0.83 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL13981611 | 0.83 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL30936834 | 0.82 | KMT2A (0.40) | ALDH1A1LMNAMAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390532-B2 | ALK protein regulator and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2025-08-19 | — | — | US | disclosed |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20220257776-A1 | ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-08-18 | — | — | US | disclosed |
| US-20220249482-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-08-11 | — | — | US | disclosed |
| EP-4029499-A1 | ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF | Shanghaitech University (CN) | 2022-07-20 | — | — | EP | disclosed |
| US-11253516-B2 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-02-22 | — | — | US | disclosed |
| EP-2601186-A2 | 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | ALDH1A1 214/4885LMNA 1889/4885MAPT 2815/4885 |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | EGFR, KRAS, ERBB2 | ALDH1A1 2871/4885LMNA 4456/4885MAPT 3977/4885 |
| US-12390532-B2 | ALK protein regulator and anti-tumor application thereof | ALK, MYC, ALKBH3 | ALDH1A1 1743/4885LMNA 3426/4885MAPT 4564/4885 |
| US-20220257776-A1 | ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF | ALK, MYC, ALKBH3 | ALDH1A1 1743/4885LMNA 3426/4885MAPT 4564/4885 |
| US-20220249482-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | FLT3, EGFR, ERBB2 | ALDH1A1 2330/4885LMNA 3636/4885MAPT 4112/4885 |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | ADRM1, VHL, MDM2 | ALDH1A1 1038/4885LMNA 986/4885MAPT 2785/4885 |
| US-11253516-B2 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | FLT3, EGFR, ERBB2 | ALDH1A1 2330/4885LMNA 3636/4885MAPT 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.